Compare Becton Dickinson and Co (BDX) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs D Wave Quantum Inc — how do they compare? Becton Dickinson and Co trades at $155.86 (market cap $41.51B), while D Wave Quantum Inc trades at $18.24 (market cap $7.02B). The key difference: Becton Dickinson and Co is far larger — about 5.9× D Wave Quantum Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals.
| BDX | QBTS | |
|---|---|---|
Market Cap | $41.51B | $7.02B |
Sector | Health | Technology |
52-Week High | $185.39 | $44.78 |
52-Week Low | $135.49 | $12.98 |
Enterprise Value | $57.97B | $6.48B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
QBTS trades at $18.67, down 7.05% today amid a broader quantum computing sector sell-off. The stock exhibits a bearish technical signal despite oversold RSI readings, while fundamentals reveal severe losses with a net income margin of -2,957.23% and negative cash flow from operations. Recent news highlights its Nasdaq listing transfer and IDC MarketScape recognition as a quantum computing leader.
Analyst consensus remains strongly bullish with a $39.86 price target, but the stock faces significant execution risks, cash burn, and intense competition. Investment appeal hinges on speculative growth in commercial quantum adoption, yet profitability remains distant, demanding high risk tolerance from investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
